| Literature DB >> 35470069 |
Noha M Hammad1, Maysaa A Saeed2, Shaker Wagih Shaltout3, Hanaa A Nofal4, Ramadan M Nafae5, Kadem Arslan6, Alpaslan Tanoglu7, Mihai Nechifor8, Catalina Luca8, Zaid Hashim Ali Al-Kadhim9, Ahmed Mosallem10, Fatma A Amer11.
Abstract
BACKGROUND: It has been found that patients recovered from COVID 19 may still test Reverse Transcriptase- Polymerase Chain Reaction (RT- PCR) positive without being infectious; the reasons are unclear. The occurrence of false-negative results of RT- PCR interferes with a proper diagnosis. The objectives of that work were to determine factors associated with persistently detectable SARS-CoV-2 RNA among recovered hospitalized patients and to determine the incidence of false-negative RT-PCR results and associated factors.Entities:
Keywords: COVID 19; Conversion time; False-negative; RT-PCR
Mesh:
Substances:
Year: 2022 PMID: 35470069 PMCID: PMC9023367 DOI: 10.1016/j.tmaid.2022.102334
Source DB: PubMed Journal: Travel Med Infect Dis ISSN: 1477-8939 Impact factor: 20.441
RT- PCR platforms, RT-PCR kits, and cycle threshold for negative sample in different referral canters.
| Country | RT- PCR Platforms | Real time PCR kit | Negative Ct value |
|---|---|---|---|
| Egypt | -Applied Biosystems ABI 7500 Fast | - LiliF™ COVID-19 Multi Real-Time RT-PCR Kit (Intron Biotechnology) | -No Ct values reported or Ct value > 35 |
| -QuantStudio 5 Dx | -TaqPath™ COVID-19 Combo Kit (Thermo Fischer Scientific) | -No Ct values reported or Ct value ≥ 40 | |
| -BioRad CFX96 Touch | -Allplex™ SARS-CoV-2 Assay (Seegene) | -No Ct values reported or Ct value > 40 | |
| Iraq | -BioRad iCycler IQ | SARS-CoV-2 Nucleic Acid Detection Kit (Zybio Inc) | No Ct values reported or Ct value ≥ 40 |
| Turkey | -BioRad iCycler IQ | -Bio-Speedy SARS CoV-2 Double Gene RT-qPCR (Bioeksen R&D Technologies Ltd.) | -No Ct values reported or Ct value ≥ 38 |
| Romania | -Applied Biosystems 7500 Fast Dx | -PowerCheck 2019-nCoV Real-Time PCR Kit (Kogene Biotech) | -No Ct values reported or Ct value ≥ 40 |
RT-PCR, reverse transcription polymerase chain reaction; Ct, cycle threshold.
Port Said University Hospital.
Zagazig University Hospital.
Altaiseer Private Hospital.
Fig. 1Distribution of early and prolonged RT-PCR conversion time among the study participants.
Fig. 2Detailed distribution of RT-PCR conversion time among the study participants.
Sociodemographic characteristics and clinical features and their effect on length of persistence of COVID- 19 RNA.
| Variable | ≤20 days (n = 363) n (%) | >20 days (n = 119) n (%) | |
|---|---|---|---|
| Age | 0.25 | ||
| - ≤29 years | 21(5.8) | 3(2.5) | |
| - 30–39 years | 52(14.3) | 14(11.8) | |
| - 40–49 years | 62(17.1) | 16(13.4) | |
| - 50–59 years | 84(23.1) | 28(23.5) | |
| - 60–69 years | 80(22.0) | 32(26.9) | |
| - 70–79 years | 46(12.7) | 14(11.8) | |
| - ≥80 years | 18(5.0) | 12(10.1) | |
| Contact of COVID-19 | 0.001 | ||
| - No | 139(38.3) | 26(21.8) | |
| - Yes | 224(61.7) | 93 (78.2) | |
| Smoking | 0.57 | ||
| - No | 245 (67.5) | 77 (64.7) | |
| - Yes | 118(32.5) | 42 (35.3) | |
| Symptoms | |||
| - Cough | 293(80.7) | 100(84.0) | 0.41 |
| - Body aches | 273 (75.2) | 84 (70.6) | 0.31 |
| - Fever | 246(67.8) | 99 (83.2) | 0.001 |
| - Dyspnea | 198 (54.5) | 73 (61.3) | 0.19 |
| - Headache | 198(54.5) | 44(37.0) | 0.001 |
| - Expectoration | 89(24.5) | 26(21.8) | 0.55 |
| - Sore throat | 127(35.0) | 28 (23.5) | 0.02 |
| - Digestive symptoms: | |||
Epigastric pain and vomiting | 14(3.9) | 8(6.7) | 0.19 |
Diarrhea | 273(75.2) | 88(73.9) | 0.78 |
| - Loss of smell | 145(39.9) | 20(16.8) | <0.001 |
| - Loss of taste | 120(33.1) | 16 (13.4) | <0.001 |
| Days of symptoms before admission | <0.001 | ||
| - < 7 days | 253(69.7) | 60(50.4) | |
| - ≥ 7 days | 110(30.3) | 59(49.6) | |
| Comorbidity | |||
| - Hypertension | 158(43.5) | 67(56.3) | 0.01 |
| - Diabetes | 95(26.2) | 45 (37.8) | 0.015 |
| - Ischemic heart disease | 56(15.4) | 18(15.1) | 0.93 |
| - COPD | 28(7.7) | 24(20.2) | <0.001 |
| - Others | 71 (22.7) | 45(26.6) | 0.33 |
Coronavirus disease 2019, COVID-2019; RNA, ribonucleic acid; COPD, chronic obstructive pulmonary disease.
Significant difference.
Others included heart failure (5.6%), renal disease (8.7%), hepatic disease (8.9%), bronchial asthma (9.3%), immunosuppressive illness (2.7%), HIV (0.4%) and other illnesses (2.1%).
Laboratory parameters, CT imaging, medications, and patient outcome and their association with length of persistence of COVID- 19 RNA.
| Variable | ≤20 days (n = 363) n (%) | >20 days (n = 119) n (%) | |
|---|---|---|---|
| Total Leucocytic count | |||
| - Leukopenia | 72 (19.8) | 17(14.3) | 0.03 |
| - Leukocytosis | 105 (28.9) | 49(41.2) | |
| Neutrophils | |||
| - Neutropenia | 73 (19.1) | 23(19.3) | 0.03 |
| - Neutrophilia | 113 (31.2) | 51(42.8) | |
| Lymphocytes | |||
| - Lymphopenia | 253 (69.7) | 92(77.3) | 0.002 |
| - Lymphocytosis | 23 (6.3) | 5(4.2) | |
| Platelets | |||
| - Thrombocytopenia | 34 (9.4) | 18 (15.1) | 0.07 |
| ESR | <0.001 | ||
| - Normal | 124 (34.2) | 16(13.8) | |
| - Elevated | 239 (65.8) | 103 (86.6) | |
| CRP | 0.04 | ||
| - Normal | 23 (6.3) | 2(1.7) | |
| - Elevated | 340(93.7) | 117(98.3) | |
| LDH a (U/L) | 259(188–403.75) | 366(217–610) | 0.007 |
| D dimer a (ng/mL) | 585(0.94–935.0) | 807.5(0.81–.1987) | 0.5 |
| Ferritin a (ng/mL) | 332(150–552) | 540(345–540) | 0.04 |
| ALT serum level | 0.15 | ||
| - Normal | 234(64.5) | 68(57.1) | |
| - Elevated | 129(35.5) | 51(42.9) | |
| AST serum level | 0.25 | ||
| - Normal | 261(71.9) | 79(66.4) | |
| - Elevated | 102(28.1) | 40(33.6) | |
| Serum creatinine level | 0.001 | ||
| - Normal | 296(81.5) | 79(66.4) | |
| - Elevated | 67(18.5) | 40 (33.6) | |
| Blood glucose level | 0.006 | ||
| - Hypoglycemia | 7(1.9) | 0(0.0) | |
| - Hyperglycemia | 125(34.4) | 59 (49.6) | |
| - Euglycemia | 231(63.6) | 60(50.4) | |
| Radiological findings | <0.001 | ||
| - Presence of GGO and consolidation | 146(40.2) | 76(93.6) | |
| - Presence of GGO without consolidation | 119(32.8) | 36(30.3) | |
| - Presence of consolidation without GGO | 52(14.3) | 6(5.0) | |
| <0.001 | |||
| - One lobe | 15(4.1) | 4(3.4) | |
| - Two lobes | 80(22.0) | 15(12.6) | |
| - Three lobes | 115(31.7) | 42(35.3) | |
| - Four lobes | 83(22.9) | 43(36.1) | |
| - Five lobes | 24(6.6) | 14(11.8) | |
| 0.003 | |||
| - Unilateral | 29(8.0) | 9(7.6) | |
| - Bilateral | 289(79.6) | 108(90.8) | |
| Medications | |||
| -Steroids | 229(70.2) | 97(29.8) | <0.001 |
| -Anticoagulants | 292(71.2) | 118(28.8) | <0.001 |
| -Antibiotics | 292(71.2) | 113(27.9) | <0.001 |
| -Antiviral | |||
Ivermectin | 147 (75.4) | 48 (24.6) | 0.97 |
Remdesivir | 26(61.9) | 16(38.1) | 0.03 |
Favipravir | 114 (76.5) | 35(23.5) | 0.68 |
| -Others | 108(92.3) | 9(7.7) | <0.001 |
| Outcome | 0.01 | ||
| - Discharged | 327(90.1) | 97(81.5) | |
| - Died | 36(9.9) | 22(17.5) |
CT; computed topography, COVID-19; Coronavirus disease 2019, RNA; ribonucleic acid, COPD; chronic obstructive pulmonary disease.
Significant difference.
Median (Interquartile range).
Others include analgesics and antipyretics, antioxidants, lactoferrin, vitamin D, vitamin C, and Zinc.
Multivariable binary logistic regression analysis to detect predictors of conversion time.
| Variable | B | S.E. | P-value | Odds ratio | 95% CI | |
|---|---|---|---|---|---|---|
| lower | upper | |||||
| Demographic characteristics | 0.93 | 3.11 | ||||
| -Recent contact to covid-19 case | 0.53 | 0.30 | 0.07 | 1.71 | ||
| Symptoms | ||||||
| -Fever | 1.23 | 0.36 | 0.001 | 3.43 | 1.66 | 7.05 |
| -Headache | −0.83 | 0.29 | 0.005 | 0.45 | 0.25 | 0.78 |
| History of illness | ||||||
| -Hypertension | 1.06 | 0.31 | 0.001 | 2.88 | 1.37 | 4.37 |
| -Diabetes | 0.60 | 0.34 | 0.07 | 1.83 | 0.93 | 3.58 |
| -Ischemic heart disease | −0.60 | 0.37 | 0.11 | 0.54 | 0.26 | 1.13 |
| -COPD | 0.93 | 0.40 | 0.02 | 2.54 | 1.15 | 5.63 |
| Laboratory findings | ||||||
| -Leukocytosis | 0.105 | 0.190 | 0.57 | 1.11 | 0.76 | 1.61 |
| -Neutrophilia | 0.09 | 0.10 | 0.36 | 1.10 | 0.89 | 1.36 |
| -Lymphopenia | −0.15 | 0.09 | 0.05 | 0.83 | 0.70 | 0.99 |
| -Thrombocytopenia | −0.16 | 0.19 | 0.47 | 0.84 | 0.57 | 1.25 |
| -ESR | 0.83 | 0.33 | 0.01 | 2.30 | 1.19 | 4.43 |
| -Elevated ALT | 0.083 | 0.38 | 0.82 | 1.08 | 0.51 | 2.03 |
| -Elevated AST | −0.28 | 0.43 | 0.51 | 0.75 | 0.31 | 1.75 |
| -Elevated serum creatinine | 0.22 | 0.34 | 0.52 | 1.24 | 0.63 | 2.45 |
| -Hyperglycaemia | 0.35 | 0.33 | 0.28 | 1.43 | 0.74 | 2.73 |
| Radiologic findings | ||||||
| -CT chest pattern | 0.02 | 0.2 | 0.89 | 1.02 | 0.68 | 1.54 |
| -Number of lobes affected | 0.73 | 0.34 | 0.04 | 1.28 | 1.07 | 2.70 |
| -Lung disease (Bilateralism) | 0.65 | 0.38 | 0.035 | 1.5 | 1.03 | 3.2 |
S.E.; standard error, CI; Confidence interval, COVID-19; Coronavirus disease 2019, COPD; chronic obstructive pulmonary disease, ESR; erythrocyte sedimentation rate, ALT; alanine transaminase, AST; aspartate transaminase, CT; computed topography.
Significant difference.
Fig. 3The distribution of the initial RT-PCR test results among the study participants.
Initial false-negative RT-PCR.
| Variable | n = 18 | % |
|---|---|---|
| - ≤29 years | 1 | 5.6 |
| - 30–39 years | 5 | 27.8 |
| - 40–49 years | 2 | 11.1 |
| - 50–59 years | 7 | 39.8 |
| - 60–69 years | 3 | 16.7 |
| Recent Contact to COVID 19 case | ||
| - No | 12 | 66.7 |
| - Yes | 6 | 33.3 |
| RT-PCR conversion time | ||
| - <3 weeks | 10 | 55.6 |
| - ≥ 3 weeks | 8 | 44.4 |
| Days of symptoms before admission | ||
| - < 7 days | 17 | 94.4 |
| - ≥ 7 days | 1 | 5.6 |
| Radiological findings | ||
| - Presence of GGO and consolidation | 6 | 33.3 |
| - Presence of GGO without consolidation | 10 | 55.6 |
| - Presence of consolidation without GGO | 2 | 11.1 |
| - One lobe | 0 | 0 |
| - Two lobes | 2 | 11.1 |
| - Three lobes | 11 | 61.1 |
| - Four lobes | 5 | 27.8 |
| - Five lobes | 0 | 0 |
| -Unilateral | 0 | 0 |
| -Bilateral | 18 | 100.0 |
| 2nd RT- PCR | ||
| - Positive | 18 | 100.0 |
| - Negative | 0 | 0.0 |
| Outcome | ||
| - Discharged | 17 | 94.4 |
| - Died | 1 | 5.6 |
RT-PCR, reverse transcription polymerase chain reaction, CT; computed topography, GGO; ground glass opacity.